Biotechnology Apellis Initiates Registrational Programs of Pegcetacoplan in Patients with C3G / IC-MPGN and ALS, Rare Diseases with High Unmet Need October 5, 2020
Biotechnology argenx Presents Additional Efgartigimod Data from Global Phase 3 ADAPT Trial at the Myasthenia Gravis Foundation of America 2020 Scientific Session October 5, 2020
Biotechnology Apellis Announces New Analysis Demonstrating Targeted C3 Therapy Pegcetacoplan Slows Progression of Early Disease in Patients with Geographic Atrophy (GA) October 3, 2020
Biotechnology ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against BioMarin Pharmaceutical Inc.; Encourages Investors with Losses in Excess of $100K to Contact Firm – BMRN October 2, 2020
Biotechnology BioMarin, Pioneer in Phenylketonuria (PKU) and Gene Therapy, Receives FDA Fast Track Designation for PKU Investigational Gene Therapy, BMN 307 October 2, 2020
Biotechnology BMRN INVESTOR FRAUD: Hagens Berman, National Trial Attorneys, Encourages BioMarin Pharmaceutical (BMRN) Investors to Contact Its Attorneys, Securities Fraud Class Action Filed October 1, 2020
Search
Biotechnology
October 2, 2020
